Drugs / SLC-0111
SLC-0111
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02215850 | Oct 2014 → Mar 2016 | cancer | Welichem Biotech Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03450018 | Jan 2019 → May 2024 | pancreatic ductal adenocarcinoma | British Columbia Cancer Agency | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SLC-0111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03450018 ↗ |
| Known as | 4-{[(4'-fluorophenyl)carbamoyl]amino}benzenesulfonamide | ChEMBL registry synonym — accepted as the source's own label CHEMBL1615281 ↗ |
| Known as | NSC-213841 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1615281 ↗ |
| Known as | U-104 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1615281 ↗ |
| Action | Inhibit | “inhibitor of carbonic anhydrase (CA) IX” NCT02215850 ↗ |
| Modality | Small molecule | “selective, small molecule, inhibitor” NCT02215850 ↗ |
| Route | Oral | “SLC-0111 (oral)” NCT03450018 ↗ |